Recap: Nevro Q4 Earnings
Shares of Nevro (NYSE:NVRO) moved lower in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 52.27% year over year to ($0.21), which beat the estimate of ($0.33).
Revenue of $109,731,000 declined by 4.06% from the same period last year, which beat the estimate of $107,430,000.
Guidance
Nevro Sees Q1 Sales Of $84M-$86M Vs $94.23M Estimates
Conference Call Details
Date: Feb 24, 2021
Time: 04:30 PM
Technicals
Company's 52-week high was at $188.14
Company's 52-week low was at $65.05
Price action over last quarter: Up 6.73%
Company Profile
Nevro Corp is a medical device company. Its key product is the Senza spinal cord stimulation system, a neuromodulation platform for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. Nevro generates the majority of its revenue in the United States. It also receives nearly half of its revenue from Australia, the United Kingdom, and Germany.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
